Cell therapy for macular degeneration—first phase I/II pluripotent stem cell-based clinical trial shows promise by unknown
SCIENCE CHINA 
Life Sciences 
© The Author(s) 2014. This article is published with open access at link.springer.com life.scichina.com   link.springer.com 
                  
*Corresponding author (email: chenzhiguo@gmail.com; yaz@bjsap.org) 
• RESEARCH HIGHLIGHT • January 2015  Vol.58  No.1: 119–120 
 doi: 10.1007/s11427-014-4791-2  
Cell therapy for macular degeneration—first phase I/II pluripotent 
stem cell-based clinical trial shows promise 
CHEN ZhiGuo1,2* & ZHANG Y. Alex1,2* 
1Cell Therapy Center, Xuanwu Hospital, Capital Medical University, and Key Laboratory of Neurodegeneration, Ministry of Education, 
Beijing 100053, China; 
2Center of Neural Injury and Repair, Beijing Institute for Brain Disorders, Beijing 100069, China 
Received November 20, 2014; accepted November 28, 2014; published online December 18, 2014 
 
Citation:  Chen ZG, Zhang YA. Cell therapy for macular degeneration—first phase I/II pluripotent stem cell-based clinical trial shows promise. Sci China Life 




Embryonic stem (ES) cells, a type of pluripotent stem cells 
(PSCs) that are derived from the inner cell mass of blasto-
cysts, have been discovered for more than three decades [1]. 
Given the almost infinite self-renewal capacity and the po-
tential to differentiate into any specific cell type in an indi-
vidual, ES cells and PSCs have brought hope for the treat-
ment of many unmet diseases. However, the advantages of 
PSCs—the highly proliferative and plastic capacities, also 
give rise to concerns regarding the development of tumors 
and differentiation of undesirable cell types, when engrafted 
into a human being. These concerns have hampered the ap-
plication of PSCs in clinics and not until 2010 was the first 
clinical trial using PSC-derived cells approved in the world. 
The long awaited medium- to long-term results of the trials 
that came out in a recent Lancet publication confirmed that 
hESC-derived cells improved vision in macular degenera-
tion patients while showing no apparent safety concerns [2], 
bringing much relief to some and considerable excitement 
to many in the stem cell field. 
Macular degeneration is the leading cause of blindness in 
developed countries, which involves degeneration of retinal 
pigment epithelial (RPE) cells leading to photoreceptor loss 
and deterioration of visual acuity. Because eyes are im-
mune-privileged organ and require only a relatively small 
dose of cells to show efficacy, macular degeneration has 
become the first-in-human clinical trial approved that in-
volves the use of PSCs. In 2010, the US Food and Drug 
Administration approved the application of ES cells-derived 
RPE cells for subretinal delivery to treat macular degenera-
tion in humans and the first patient was enrolled in 2011 
(ClinicalTrials.gov, numbers NCT01345006 and NCT0134- 
4993).  
The short-term follow-up results from two registered pa-
tients were published in Lancet in 2012 [3]. And the recent 
Lancet publication provided the medium- and long-term 
follow-up results with 18 enrolled patients, including nine 
dry age-related macular degeneration and nine Stargardt’s 
macular dystrophy patients [2]. The nine patients of either 
disease were further divided into three groups, with each 
group receiving 50,000, 100,000, and 150,000 RPE cells, 
respectively. The RPE cells were differentiated from ES 
cells using a previously established protocol, which yielded 
homogeneous RPE cells of more than 99% purity. Prior to 
transplantation, the best-corrected visual acuity in the study 
eyes ranged from 20/200 (severe vision loss) to hand mo-
tion (near blindness). For patients in both study groups, 
treated eyes have shown more improvement from baseline 
as compared to the untreated eyes. In total, eight of the 18 
patients experienced an increase in visual acuity of at least 
15 letters one year after transplantation, which corresponds 
to doubling of the visual angle, and is generally accepted as 
a clinically significant improvement. By using a sensitive 
and reliable Visual Function Questionnaire, trained exam-
iners measured the vision-targeted quality of life for the 
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patients before and at various time points after transplanta-
tion. For age-related macular degeneration, the mental 
health and vision subscales for general vision, peripheral 
vision, near activities, and distance activities improved from 
baseline by a median of 1625 points 312 months after 
transplantation. For patients with Stargardt’s macular dys-
trophy, there was an improvement of 820 points 312 
months after transplantation.  
Compared to the efficacy of improving vision, more at-
tention was probably paid to the safety profile of the trials, 
in particular, whether there was any indication of tumor 
formation. The median follow-up time in the reported study 
was 22 months, with the longest one up to 37 months. With 
this medium- to long-term follow-up time, no safety issues 
related to the engrafted cells were observed. No occurrences 
of adverse proliferation, growth of transplanted tissue at the 
injection site, or differentiation to ectopic tissue/cells 
(non-RPE cells) was observed. No sign of acute transplant 
rejection was noted in any of the operated eyes. Although a 
small extent of preretinal, pigmented cell growth was seen 
in three eyes near the injection site, no adverse effects were 
caused by these small epiretinal pigmented cell patches, 
which was considered to be a visually insignificant event. 
Several systemic adverse events observed in patients seem 
to be related to the regimen of immune suppression, which 
started from one week before and through 12 weeks after 
transplantation.  
The improvement of visual acuity may not be conclu-
sively approved because of the inherent caveats of 
open-label trials, which, as the authors have discussed, may 
include the possibilities of sham-surgery rescue effect, pla-
cebo effect, and improvement due to repeated testing and 
intersession variability. However, the current trial has pro-
vided quite solid ground for the safety of this interventional 
strategy, which itself is a major step forward in stem cell-
therapy involving PSCs.  
As noted above, some complications observed in the 
study were actually associated with the immunosuppression 
regimen. The side effects were particularly obvious in el-
derly patients. Another source of PSCs—induced pluripo-
tent stem cells (iPSCs) may circumvent such problems. iP-
SCs can be derived from patients’ own somatic cells and 
possess almost identical genomic background [4]. In July 
2013, Japan approved the first clinical trial using iPS 
cells-derived RPE cells for treatment of macular degenera-
tion, which was led by ophthalmologist Masayo Takahashi 
at the RIKEN Center for Developmental Biology (CDB) in 
Kobe, Japan. On September 12, 2014, the first woman re-
ceived transplantation of iPSC-derived RPE cells to treat 
macular degeneration.  
Stem cell therapy is a rapidly progressing field. If ES- 
and/or iPSC-derived RPE cells are proved to be safe and 
efficacious for treatment of macular degeneration, it will 
have a significant impact on the regulatory bodies in other 
nations and accelerate the clinical translation of cell therapy 
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